With lipid nanoparticles moving beyond mRNA vaccines, biopharma are racing against the clock to exploit clinical utility to deliver more complex payloads, while optimising scalability and product quality.

Following industry progress of BioNTech entering LNP cancer vaccine trials, Moderna entering $76m collaboration with Gen Bio, and Bayer-Acuitas Therapeutics partnership using LNP for gene therapy, the field showed no signs of slowing down.

In collaboration with CPI, Pfizer, GSK, this 3-day summit reunited 100+ senior leaders, sharing exclusive data to help you maximise this non-viral delivery system's potential. The 2nd Lipid Nanoparticle Development Europe Summit was committed to equipping you with actionable takeaways across end-to-end characterisation, biodistribution, formulation and scale up to supercharge your LNP pipeline development with therapeutic promise to patients.